Jaguar Animal Health Inc. (NASDAQ: JAGX) has released the topline results of a recent study of Neonorm Calf, a formulation used to manage hydration in animals suffering from naturally occurring diarrhea. The study was designed to evaluate the efficacy of a second-generation of Neonorm Calf. The target patients were preweaned dairy calves.
JAGX’s Neonorm Calf is offered in powder form but it is administered in liquid form.
The study and the outcome
Jaguar Animal Health Inc. (NASDAQ: JAGX) carried out the study of the formulation in calves with naturally occurring diarrhea in collaboration with Cornell University College of Veterinary Medicine. In addition to seeking to assess the efficacy of the treatment, JAGX and its partner were also out to investigate the prebiotic benefit of Neonorm Calf.
Jaguar Animal Health Inc. (NASDAQ: JAGX) carried out randomized, double-blind study of the product in 40 bull calves of the Holstein type. The calves were afflicted by naturally occurring diarrhea. The study compared Neonorm Calf against a placebo. The treatment was administered to the patients twice daily.
Several measurements were taken during the 25-day study period and the topline results showed positive outcome. For example, the product was found to significantly improve hydrating of the patient calves that took it as part of their treatment.
But JAGX said it will be doing a more detailed analysis of the study so that it can understand the effect of the treatment on specific end points.
Neonorm Calf is one of JAGX’s lead non-prescription products designed to help sick animals cope with diarrhea-related dehydration. The company said that making the product available in powder form is designed to simplify its administration.
Cash injection for Jaguar Animal Health Inc (NASDAQ: JAGX)
As Jaguar Animal Health Inc. (NASDAQ: JAGX) continues with the development of its various pipeline products, the company recently got financial shot in the arm. An investor called Aspire Capital Fund recently poured $14.5 million into the company through equity purchase.
The management said that the deal with Aspire provided them with the opportunity to strengthen the balance sheet and increase financial flexibility. The funds generated from the equity arrangement with Aspire are expected to help with financing clinical activities and commercialization.